Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
In Vitro Kinase Assay - Inhibition of ALK1/2/3/4/5/6 Kinases from US Patent US11702401: "Compounds and methods of use"
Assay data:33 Active, 32 Activity ≤ 1 µM, 36 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Luciferase Reporter Gene Assay for ALK2 and TGFbeta Activity from US Patent US11654147: "ALK2 inhibitors and methods for inhibiting BMP signaling"
Assay data:149 Active, 1 Activity ≤ 1 nM, 165 Activity ≤ 1 µM, 170 Tested
Inhibition of human wild type partial length BMPR1A (Q214 to I532 residues) expressed in bacterial expression system assessed as remaining activity at 1 uM relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of ALK3 (unknown origin)
Assay data:23 Active, 13 Activity ≤ 1 µM, 28 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human recombinant ALK3 (198 to 525 residues) expressed in baculovirus-infected insect cells by ADP-Glo kinase assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of GST-tagged human recombinant ALK3 expressed in insect cells using casein as substrate in presence of [gamma-32P]ATP incubated for 45 mins by Microscint-20 scintillation counting analysis
Inhibition of recombinant human N-terminal GST-tagged ALK3 (187 to 532 residues) expressed in baculovirus assessed as loss of peptide phosphorylation activity using peptide substrate in presence of ATP and measured after 1 hrs by HTRF assay
Assay data:5 Active, 4 Activity ≤ 1 µM, 5 Tested
Binding affinity to wild type ALK3 (unknown origin) assessed as percent of control at 1 uM by Kinomescan method relative to control
Inhibition of wild type ALK3 (unknown origin) assessed as enzymatic activity using chemiluminescent substrate by ADP-Glo assay
BMPR1A DiscoveRx kinase panel
SummaryRelated BioAssays by Target
Inhibition of ALK3 (unknown origin) at 1 uM
Luminescence-Based ADPGlo Kinase Activity Assay from US Patent US11160797: "Pyridinone derivatives and their use as selective ALK-2 inhibitors"
Assay data:48 Active, 43 Activity ≤ 1 µM, 48 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
ADPGlo Assay from US Patent US10947218: "Aminopyridine derivatives and their use as selective ALK-2 inhibitors"
Assay data:87 Active, 86 Activity ≤ 1 µM, 87 Tested
ADPGlo Assay from US Patent US10710980: "Aminopyridine derivatives and their use as selective ALK-2 inhibitors"
Assay data:88 Active, 87 Activity ≤ 1 µM, 88 Tested
In Vitro Kinase Assay from US Patent US10501436: "Compounds and methods of use"
Biochemical Binding Assay from US Patent US9469613: "(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide"
Enzyme Assay from US Patent US10017516: "BMP inhibitors and methods of use thereof"
Assay data:67 Active, 66 Activity ≤ 1 µM, 67 Tested
In Vitro Kinase Assay Inhibition of ALK1/2/3/4/5/6 Kinases from US Patent US10030004: "Compounds and methods of use"
ALK1-6 enzymatic assays from US Patent US9682983: "BMP inhibitors and methods of use thereof"
Assay data:66 Active, 65 Activity ≤ 1 µM, 66 Tested
KinomeScan assay: inhibition of BMPR1A
Assay data:108 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on